Skip to main content

Advertisement

Computational chemistry in pharmaceutical research – where do we stand after 25 years?

Article metrics

  • 1312 Accesses

In the early 80th of the last century molecular modeling was introduced as a tool to aid rational drug design in pharmaceutical industry. However in these early days modeling had narrow limits due to the lack of adequate compute power and sophisticated methods. There was a large gap between expectations of medicinal chemists and the power of theoretical methods. Today computational chemistry is an integral part of pharmaceutical research. What has changed over the last decades, what was the driving force of the progress?

The talk is based on the author’s experience at Boehringer Ingelheim and will focus on computational chemistry methods with proven value in industrial pharmaceutical research. Amongst others the synergy of virtual screening and combinatorial chemistry and the impact of the recently published structures of GPCRs on pharmaceutical research will be illustrated. Further current challenges, e.g. the consideration of protein flexibility, will be discussed.

Author information

Correspondence to Herbert Köppen.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Köppen, H. Computational chemistry in pharmaceutical research – where do we stand after 25 years?. J Cheminform 4, O19 (2012) doi:10.1186/1758-2946-4-S1-O19

Download citation

Keywords

  • Pharmaceutical Industry
  • Chemistry Method
  • Century Molecular Modeling
  • Drug Design
  • Virtual Screening